Pattarapan Pharm D Sukwuttichai

Pattarapan Pharm D Sukwuttichai

Auto-generated profile, based on publicly available information

Pattarapan Pharm D Sukwuttichai

Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2026 in Journal of Global Health
Verified
Journal Article
Open access
PSPattarapan Sukwuttichai
Pattarapan Sukwuttichai
NTNattapong Tidwong
Nattapong Tidwong
NCNatapohn Chaipichit
Natapohn Chaipichit
TDTeerapon Dhippayom
Teerapon Dhippayom
WDWitoo Dilokthornsakul
Witoo Dilokthornsakul
Piyameth DilokthornsakulPiyameth Dilokthornsakul
Piyameth Dilokthornsakul
Iron is a micronutrient that plays a critical role in oxygen transportation, energy production, and overall physiological growth at every stage of life. About 70% of the body’s total iron is localised in red blood cells (haemoglobin) and muscle cells (myoglobin), where it facilitates the efficient delivery and utilisation of oxygen [1]. During childhood, iron […]

25 June 2024 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
SKSunisa Pharm D Khamlek
Sunisa Pharm D Khamlek
ALAroonrut Lucksiri
Aroonrut Lucksiri
KSKanokkarn Sunkonkit
Kanokkarn Sunkonkit
POPeninnah Oberdorfer
Peninnah Oberdorfer
PSPattarapan Pharm D Sukwuttichai
Pattarapan Pharm D Sukwuttichai
Background: This study aimed to investigate the efficacy and safety of intravenous colistin in pediatric patients with nosocomial Gram-negative bacteria infections and to determine factors associated with treatment outcomes. Methods: This retrospective study recruited patients <18 years of age receiving intravenous colistin between January 2014 and December 2018. Clinical data and treatment outcomes were reviewed, and factors associated with treatment outcomes were assessed. Results: This study included 178 patients with a median age of 3.4 years (range, 0.1–17.8). The mean ± SD dose of colistin prescribed to patients without renal impairment was 5.1 ± 0.6 mg/kg/day. The clinical response rate was 70.8% in patients receiving colistin for specific treatment. Infection-related mortality and crude mortality were 17.5% and 19.7%, respectively. The nephrotoxicity rate was 29.8%; approximately 70% of the episodes occurred between the 3rd and 7th day of treatment. The presence of at least 2 organ dysfunctions [adjusted hazard ratio (aHR): 7.17; 95% CI: 1.64–31.40], septic shock (aHR: 2.69; 95% CI: 1.36–5.32) and receiving chemotherapy/immunosuppressants (aHR: 2.68; 95% CI: 1.36–5.25) were observed to be associated with clinical failure. The factors observed to be associated with nephrotoxicity included hypoalbuminemia (aHR: 2.93; 95% CI: 1.26–6.78), receiving amphotericin B (aHR: 2.29; 95% CI: 1.16–4.52), vancomycin (aHR: 3.36; 95% CI: 1.50–7.56) and vasopressors (aHR: 2.57; 95% CI: 1.27–5.21). Conclusion: Colistin is generally effective in the treatment of nosocomial Gram-negative bacteria infections in pediatric patients. Close monitoring of renal function should be considered, especially in high-risk patients. Optimal dosage regimens for pediatric populations to promote more favorable clinical outcomes and minimize nephrotoxicity require further investigation.